Biowaiver approach for biopharmaceutics classification system class 3 compound metformin hydrochloride using In Silico modeling

Journal of Pharmaceutical Sciences

Volumn 101, Issue 5, 2012, Pages 1773-1782

  Crison, John R ^a   Timmins, Peter ^a   Keung, Anther ^a   Upreti, Vijay V ^a   Boulton, David W ^a   Scheer, Barry J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Biopharmaceutics Classification System (BCS); Dissolution; Mathematical model; Oral absorption; Permeability

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; COMPUTER MODEL; DRUG ABSORPTION; DRUG DISPOSITION; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; GASTROINTESTINAL TRANSIT; HUMAN; IN VIVO STUDY; INTESTINAL TRANSIT TIME; MAXIMUM PLASMA CONCENTRATION; BLOOD; CLASSIFICATION; PHARMACEUTICS; PHARMACOKINETICS; SOLUBILITY; THEORETICAL MODEL;

AREA UNDER CURVE; BIOPHARMACEUTICS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MODELS, THEORETICAL; SOLUBILITY; THERAPEUTIC EQUIVALENCY;

EID: 84863220233     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23063     Document Type: Article

References (32)

1. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinmann B. 2006. Management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 29:1963-1972.
2. Bretnall AE, Clarke GS. 1998. Metformin hydrochloride. In Analytical profiles of drug substances and Excipients; Brittain HG, Ed. Vol. 25. San Diego, California: Academic Press, pp 243-293.
3. Nicklin P, Keates AC, Page T, Bailey CJ. 1996. Transfer of metformin across monolayes of human intestinal Caco-2 cells and across rat intestine. Int J Pharm 128:155-162.
4. Proctor WR, Bourdet DL, Thakker DR. 2008. Mechanisms underlying saturable intestinal absorption of metformin. Drug Metab Dispos 36:1650-1658.
5. Tucker GT, Casey C, Phillips PJ, Conor H, Ward JD, Woods HF. 1981. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12:235-246.
6. Zhou M, Xia L, Wang J. 2007. Metformin transport by a newly-cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 35:1956-1962.
7. Shu Y, Brown C, Castro RA. 2008. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharm Ther 83:273-280.
8. Song, NN, Li QS, Lui CX. 2006. Intestinal permeability of metformin using single-pass intestinal perfusion in rats. World J Gastroent 12(25):4064-4070.
9. Cheng CL, Yu LX, Lee HL, Yang CY, Lue CS, Chou CH. 2004. Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: Bridging evidence for metformin immediate-release tablet. Eur J Pharm Sci 22:297-304.
10. Guidance for industry. 2000. Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a Biopharmaceutics Classification System. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Silver Spring, MD.
11. Blume HH, Schug BH. 1996. The Biopharmaceutics Classification System (BCS): Class III drugs-Better candidates for BA/BE waiver? Eur J Pharm Sci 9:117-121.
12. Jantratid E, Prakongpan S, Dressman JB, Amidon GL, Junginger HE, Midha KK, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Cimetidine. J Pharm Sci 95:974-984.
13. Kortejarvi H, Urtti A, Yliperttula M. 2007. Pharmacokinetic simulation of biowaiver criteria: The effects of gastric emptying, dissolution, absorption, and elimination rates. Eur J Pharm Sci 30(2):155-166.
14. Homsek I, Parojcic J, Dacevic M, Petrovic L, Javanovic D. 2010. Justification of metformin hydrochloride biowaiver criteria based on bioequivalence study. Arzneimittelforschung 60(9):553-559.
15. Jantratid E, Prakongpan S, Amidon GL, Dressman JB. 2006. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products. Cimetidine. Clin Pharmacokinet 45:385-399.
16. Tsume Y, Amidon GL. 2010. The Biowaiver extension for BCS class III drugs: The effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation. Mol Pharm 7(4):1295-1243.
17. EMEA Committee for Medicinal Products for Human Use 2010. Guideline on the Investigation of Bioequivalence, European Medicines Agency, London.
18. Glucophage®, Glucophage XR® Package Insert, Bristol-Myers Squibb Company, Princeton, NJ.
19. Marathe P, Greene D, Rashmi B, Wen Y, Crison J, Timmins P. Use of a pharmacokinetic absorption model and site of absorption studies to design modified release formulations for BCS 3 compounds. Third PharmSciFair, Pharmaceutical Sciences for the Future of Medicines. June 13-17, 2011. Prague, Czech Republic.
20. Fagerholm U, Johansson M, Lennernas H. 1996. Comparison between permeability coefficients in rat and human jejunum. Pharm Res 13(9):1336-1342.
21. Guidance for industry. 2001. Statistical approaches to establishing bioequivalence. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Silver Spring, MD.
22. Higuchi T. 1961. Rate of release of medicaments from an ointment base containing drugs in suspension. J Pharm Sci 50(10):874-875.
23. Hixson AW, Crowell JH. 1931. Dependence of reaction velocity upon surface and agitation. Ind Eng Chem 23:923-931.
24. Moore JW, Flanner HH. 1996. Mathematical comparison of dissolution profiles. Pharm Technol 20(6):64-75.
25. Guidance for Industry. 1997. Dissolution testing of immediate release solid oral dosage forms. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Silver Spring, MD.
26. Amidon GE, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a Biopharmaceutical Drug Classification System: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
27. Polli JE, Singh Rekhi G, Augsburger LL, Shah VP. 1997. Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets. J Pharm Sci 86:690-700.
28. Chow SC, Ki FYC. 1997. Statistical comparisons between dissolution profiles of drug products. J Biopharm Stat 7:241-258.
29. 2. Pharm Res 15(6):889-896.
30. Rowland M, Peck C, Tucker G. 2011. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 51:45-73.
31. Zhang X, Lionberger RA, Davit BM, Yu LX. 2011. Utility of physiologically based absorption modeling in implementing quality by design in drug development. AAPS J 13(1):59-71.
32. Sinko PJ, Leesman GD, Amidon GL. 1991. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm Res 8(8):979-988.